Skip to main content
PMC home page
BMC Urology logoLink to BMC Urology
. 2008 Sep 26;8:12. doi: 10.1186/1471-2490-8-12

RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma

Hossein Tezval 1, Axel S Merseburger 1, Ira Matuschek 1, Stefan Machtens 2, Markus A Kuczyk 1, Jürgen Serth 1,✉
PMCID: PMC2572051  PMID: 18822131

Abstract

Background

Epigenetic silencing of RAS association family 1A (RASSF1A) tumor suppressor gene occurs in various histological subtypes of renal cell carcinoma (RCC) but RASSF1A protein expression in clear cell RCC as well as a possible correlation with clinicopathological parameters of patients has not been analyzed at yet.

Methods

318 primary clear cell carcinomas were analyzed using tissue microarray analysis and immunohistochemistry. Survival analysis was carried out for 187 patients considering a follow-up period of 2–240 month.

Results

Expression of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells. RASSF1A immunopositivity was significantly associated with pT stage, group stage and histological grade of tumors and showed a tendency for impaired survival in Kaplan-Meier analysis.

Conclusion

While most tumors demonstrate a loss of RASSF1A protein, a subset of tumors was identified to exhibit substantial RASSF1A protein expression and show increased tumor progression. Thus RCC tumorigenesis without depletion of RASSF1A may be associated with an adverse clinical outcome.

Background

Clear cell renal cell carcinoma (CC-RCC) as the most frequent subtype of RCC has been described to demonstrate loss and/or alteration of chromosome 3p [1,2]. So far, some tumor suppressors and candidates have been identified on 3p, such as FHIT at 3p14.2, VHL at 3p25 and the RAS association domain family 1A gene (RASSF1A) at 3p21.3. RASSF1A has been detected to undergo promoter hypermethylation and epigenetic silencing in CC-RCC [3-7]. The RASSF1A protein contributes to cell cycle control, stabilization of microtubules, cellular adhesion and motility [8]. Moreover, RASSF1A interact with the pro-apoptotic kinase MTS1 and apoptosis-inducing interferon pathways [9,10]. Depletion of RASSF1A is associated with enhanced mitotic progression, a higher risk for chromosomal defects [11-13] pronounced cellular motility [14] and raised tumor susceptibility in knock-out mice [15].

The loss of RASSF1A function due to epigenetic gene silencing has been detected in various tumor entities, implicating that RASSF1A is involved in the pathogenesis of a wide spectrum of tumors [8]. Hypermethylation and loss of RASSF1A mRNA expression has been shown for CC-RCC in several studies. While some found methylation in tumor tissues [3-5,16-18] others reported significant methylation occurring also in normal tissue [3,6,17,18]. Considering that the detection of methylation occurring in normal tissue together with hypermethylation detected in corresponding tumor tissue might be indicative for an involvement of RASSF1A in the early tumorigenesis of CC-RCC, we have recently carried out a study explicitly aiming at the comparison of methylation in paired normal and tumoral tissues [7].

As a result we found considerable methylation in normal tissues that becomes significantly increased in corresponding tumor samples. Therefore these results support the hypothesis that RASSF1A is involved in early tumorigenesis of CC-RCC. Moreover we found that protein expression is substantially reduced in tumor cells and in a subset of normal tubular epithelial cells of histopathologically normal kidney parenchyma. While these data overall demonstrate an inverse relationship of methylation and protein levels in RCC it is not clear yet whether RASSF1A levels or the degree of epigenetic silencing is associated with clinicopathological parameters of RCC patients. So far, controversial results were reported for other tumors such as lung adenocarcinoma or non small cell lung cancer when analyzing a possible association of RASSF1A expression and grade, stage, metastasis or disease specific follow up of patients [19-22].

In this study we analyzed the presence of RASSF1A protein within the primary tumor of clear cell RCCs and benign surrounding peritumoral tissues using immunohistochemistry (IHC) and tissue microarrays (TMA) and statistically evaluated possible associations of RASSF1A protein immunopositivity and clinicopathological parameters of RCC patients.

Materials and methods

Patient characteristics and follow up

The present study included 318 patients, who underwent radical nephrectomy between 1981 and 1998. Tissue was obtained from archival routine surgical specimens. The tissue samples were selected by a pathologist and prepared from the primary tumor as well as peritumoral, histologically benign renal parenchyma and arranged on tissue micro arrays (TMA) as described previously [23]. Tumor samples were classified primarily according to UICC 1997 TNM tumor staging system [24]. At the time of the pathological assessment of our specimens the UICC 2002 version was not available. Moreover, the new pathological classification would not influence our results. Survival analysis was carried out for 187 patients with complete follow-up data and pathologically proved clear cell carcinoma of the kidney. The follow up group exhibited a median age of 57.5 years and a mean follow-up period of 83 (0–248) months (table 1). The male-to-female ratio was 1.4 to one. Seventeen patients demonstrated metastasis at the time of diagnosis whereas 170 of patients had a local tumor in the kidney. However, eighteen patients without primary metastasis developed metastases in the course of follow up. Thirty of patients without primary metastasis showed recurrence or metastasis in the course of follow-up. At the time of the last follow-up examination, 93 of patients were alive, 67 patients had died from progressive RCC and 27 patients due to other causes.

Table 1.

Patient characteristics

Variable All patients n (%) Follow-up n (%)
Total 318 (100) 187 (100)
pT stage T1 9 (3) 7 (4)
T2 157 (50) 97 (52)
T3 137 (43) 77 (41)
T4 15 (4) 6 (3)
Lymph node N0 162 (51) 96 (51)
N1 34 (11) 17 (9)
Nx 122 (38) 74 (40)
Metastasis M0 235 (74) 138 (74)
M1 63 (20) 35 (19)
Mx 20 (6) 14 (7)
pTNM stage I 10 (3) 8 (4)
II 141 (44) 88 (47)
III 100 (31) 56 (30)
IV 67 (22) 35 (19)
Tumor grade G1 53 (17) 36 (19)
G2 200 (62) 134 (72)
G3 25 (8) 10 (5)
G4 1 (0.3) 7 (4)
Unknown 39 (12) 0 (0)
Open in a new tab

Immunohistochemistry on tissue microarray sections

The paraffin-embedded TMA samples were stained for RASSF1A protein expression as described previously [7]. Evaluation of TMA's was carried out by counting immunopositive and negative cells within the area of each tissue microarray punch and the diameter of each spot on the slides were 1 mm. In tumor tissues only tumor cells were considered while in peritumoral tissue specimens the number of immunopositive and negative proximal and distal tubular cells but not glomerular cells was determined. The RASSF1A labeling index was calculated as the percentage of cells of interest displaying immunopositivity in the analyzed tissue samples (TMA's spots).

Statistical analysis

Statistical analyses were performed using the SPSS statistical software (Statistical package for social sciences, SPSS, Inc., Chicago, IL). P-values of < 0.05 were considered statistically significant. Spearman R nonparametric correlation analysis was used to determine the association between RASSF1A immunopositivity and clinicopathological parameters. The Wilcoxon-Mann-Whitney-U-test was applied for statistical comparison of RASSF1A expression as observed in distal and proximal tubules of normal kidney tissue. The possible correlation between cytoplasmic expression of RASSF1A and clinicopathological characteristics was determined by the Chi-square test. Survival was evaluated for patients with RCC of the clear cell type using the Kaplan-Meier method and the log-rank test or Cox regression analysis. Cases with cancer-independent deaths were censored at time of death and included in the analysis.

Results

Expression of RASSF1A protein

The presence of RASSF1A protein in primary tumor specimens and corresponding histologically normal surrounding parenchyma was investigated using immunohistochemical analysis of TMA slides of 318 patients with CC-RCC. Specific immunopositivity for RASSF1A was exclusively observed in the cytoplasm of tumor and normal tubular epithelial cells [7]. Positivity of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells (p < 0.001, paired t-test). In tumors a mean positivity of 19% (median 11%) was detected and 85% of tumors exhibited a RASSF1A labeling index of ≤ 25% (fig. 1 and 2).

Figure 1.

Figure 1

Open in a new tab

Differential expression of RASSF1A in clear cell carcinoma of the kidney. Immunohistochemical analysis of RASSF1A expression in CC-RCC specimens exhibiting < 25% (A) and > 25% (B) labeling index.

Figure 2.

Figure 2

Open in a new tab

Frequency plot of RASSF1A immunopositivity in CC-RCC. Frequency of RASSF1A immunopositivity (% labeling index) as observed in clear cell RCC. In approximately 85% of tumors a RASSF1A positivity of less than 25% was observed.

Considering that most of renal cell carcinomas are assumed to derive from epithelial cells of the proximal tubules labeling of RASSF1A protein both in the proximal and distal tubules of histologically normal materials were separately analyzed for a subgroup of 90 tissue samples. An almost complete staining for epithelial cells of the proximal and distal tubules with labeling index of nearly 100% was observed thus no significant difference of RASSF1A immunopositivity between proximal or distal tubules could be found (p = 0.22).

Association between RASSF1A expression and histopathological parameters

Whether a correlation between immunopositivity of RASSF1A (% labeling index) the primary tumor specimens and the histopathological grading and clinical staging of patients exists, was analyzed using Spearman R nonparametric correlation analysis. In the primary tumor specimens a positive correlation between RASSF1A expression and the pT stage (p = 0.001), histological grading (p = 0.029) and TNM group stage (p = 0.006) was detected, whereas no significant correlation was observed for lymph node metastasis (p = 0.377) and the presence of distant metastases (p = 0.41; table 2). This indicates that higher expression of RASSF1A was positively correlated with the higher pT stage, histological grading, and pTNM group stage in the entire study group.

Table 2.

Relationship of high RASSF1A labeling index (> 25%) and clinicopathological parameters for the entire study group (n = 318)

Parameter p-value*
pT-stage 0.001
Lymph node status 0.377
Metastasis 0.410
pTNM stage 0.006
Tumor grade 0.029
Open in a new tab

*Spearman nonparametric correlation analysis

Taking into account that we recently found a statistical relationship between cyclinB1 expression, as observed in the histopathological normal tissues and clinicopathological parameters [25] we also compared the RASSF1A immunopositivity detected in the paired histopathologically normal specimens to the clinicopathological parameters. No significant correlation between expression of RASSF1A protein in histopathological normal tissue and the parameters pT-stage, lymph node metastasis, distant metastasis, histological grading and TNM group stage of the patients could be detected (data not shown).

Analysis of RASSF1A protein expression and survival of patients

Using a cut-off value of 25% for the relative amount of cells positively stained for RASSF1A in primary tumor specimens, as suggested by the labeling index (fig. 1) to allow discrimination of low and high positivity tumors, a disease-specific survival analysis was performed. Increased positivity of RASSF1A in the tumor samples demonstrated a tendency towards decreased survival in Kaplan-Meier analysis with border line significance (p = 0.054, log rank test), (fig. 3). Using RASSF1A immunopositivity as a continuous variable and Cox regression for survival analysis RASSF1A was not identified as a significant parameter (p = 0.239, hazard ratio = 1.005, 95% CI 0.997–1.013).

Figure 3.

Figure 3

Open in a new tab

Kaplan-Meier analysis and Hazard Plot. Hazard plot illustration of Kaplan-Meier analysis. Disease specific survival of patients demonstrating either low (< 25% immunopositively stained tumor cells) or high immunopositivity (> 25%) is shown. Borderline significance was obtained using log rank test analysis (p = 0.054).

Discussion

RCC is staged conventionally using the TNM staging system. However comparable TNM classifications may demonstrate different clinical courses, indicating the need for additional molecular prognosticators permitting a patient specific staging and future targeted therapeutic treatment.

The role of RASSF1A as a tumor suppressor gene, its silencing and loss of function due to methylation in different tumors as well as in RCC has been reported [3-5,8,26]. Epigenetic inactivation has been observed both in clear cell and papillary RCC [4,6] however, taking into account that 85% of RCCs show clear cell carcinoma histology, only this histological subtype was considered in the present study. To our knowledge this is the first study immunohistochemically investigating a possible relationship of RASSF1A protein level with clinicopathological parameters of patients in RCC. Using tissue microarrays we were able to investigate a large series of specimens of RCC and corresponding histologically normal tissues in a single run thus, minimizing inter assay variances. Our analysis shows that in large part of tumors a loss of RASSF1A positivity is observed. Hence, our data is in concordance with previous reports describing epigenetic silencing of the gene in a substantial proportion of RCCs [4,6]. Therefore, it seems likely that decreased transcription of RASSF1A leads to a loss of RASSF1A protein, such as indicated by our study. Our analysis further supports the hypothesis that RASSF1A could be involved in tumourigenesis of a substantial part of clear cell RCC.

Interestingly, we found that a subset of tumors, showing immunopositivity comparable to that observed in morphologically normal cells, were positively correlated with T, TNM and grade of tumors. Thus, a higher positivity of RASSF1A as observed in this subgroup of tumors is significantly associated with higher stage or grade of tumors but not lymph node or distant metastasis. Moreover, supporting this finding, higher RASSF1A protein levels in tumors demonstrated a possible association with impaired survival of patients.

The clinicopathological significance of alterations of RASSF1A protein levels in tumors has not been described to our knowledge at yet. However, epigenetic silencing associated with a loss of RASSF1A has been statistically analyzed for a relationship with prognostic parameters by a few studies but showed discordant results so far. Thus it has been described that hypermethylation of RASSF1A could be associated with an adverse outcome of patients exhibiting lung cancer [19,20,27,28] whereas other studies found no relationship with prognosis [22,29-31]. Therefore, it is currently not clear whether loss of RASSF1A may serve as a negative molecular prognosticator.

Considering that in our study tumor cells showing normal levels of RASSF1A instead of the most frequently observed loss of positivity, were found to be associated with tumor progression, the question for a potential biological relevance of our findings arises.

Sporadic RCC tumourigenesis has been associated in about 60% of cases with alteration of VHL thus preventing ubiquitination and degradation of the transcription factor hyopoxia induced factor 1α (HIF-) even under normoxia in kidney cells [32]. As a consequence deregulation of pivotal cellular processes in tubular epithelial cells of the kidney, such as angiogenesis, cellular growth and acid-base balance has been described to be involved in kidney tumourigenesis. However, it is not known at yet how the presence or absence of RASSF1A in kidney tumor cells interacts with the VHL or other pathways of kidney tumorigenesis.

Loss of RASSF1A expression has been described to be involved in the majority of RCCs and likely plays a role in early RCC tumorigenesis. Thus our protein expression data may give the first evidence that RASSF1A independent RCC carcinogenesis may also occur in a subset of tumors and likely is associated with a relatively declined outcome.

Conclusion

Loss of RASSF1A protein is observed in the majority of clear cell RCC suggesting a role in RCC tumorigenesis. Depletion of RASSF1A protein is not a mandatory prerequisite of RCC development as a subset of tumors demonstrates protein levels comparable to normal cells. RCC tumorigenesis accompanied by apparently normal levels of RASSF1A is statistically associated with stage and grade of tumors and shows a tendency towards decreased survival. Therefore, it becomes clear that further studies are necessary to specifically characterize the role of RASSF1A in particular with respect to the VHL mediated tumourigenesis in RCC.

Abbreviations

CC-RCC: Clear cell renal cell carcinoma; RASSF1A: RAS association domain family 1A gene; IHC: Immunohistochemistry; TMA: Tissue microarrays; SPSS: Statistical package for social sciences; HIF-1α: Hypoxia induced factor 1α; VHL: Von Hippel-Lindau.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HT carried out the immunohistochemical analyses, statistical evaluation of data and drafting of the manuscript and figures. AM and IM participated in tissue sampling and setup of tissue microarrays and data evaluation. SM and MK participated in the design of the study and performed the analysis of patient data. JS conceived of the study, participated in its design, statistical analysis and coordination and wrote the original and final versions of the manuscript. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2490/8/12/prepub

Acknowledgments

Acknowledgements

We wish to thank B. Vaske (department of biometry, Hannover medical school) for his valuable help for statistical analysis and statistical comments on the manuscript. We acknowledge M. Hepke for her excellent technical assistance.

Contributor Information

Hossein Tezval, Email: tezval.hossein@mh-hannover.de.

Axel S Merseburger, Email: merseburger.axel@mh-hannover.de.

Ira Matuschek, Email: matuschek.ira@mh-hannover.de.

Stefan Machtens, Email: stefan.machtens@mkh-bgl.de.

Markus A Kuczyk, Email: kuczyk.markus@mh-hannover.de.

Jürgen Serth, Email: serth.juergen@mh-hannover.de.

References

  1. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007;26:7283–7301. doi: 10.1038/sj.onc.1210547. [DOI] [PubMed] [Google Scholar]
  2. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327:721–724. doi: 10.1038/327721a0. [DOI] [PubMed] [Google Scholar]
  3. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA. 2001;98:7504–7509. doi: 10.1073/pnas.131216298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001;61:7277–7281. [PubMed] [Google Scholar]
  5. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer. 2001;94:212–217. doi: 10.1002/ijc.1466. [DOI] [PubMed] [Google Scholar]
  6. Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, Pavlovich CP. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res. 2004;10:7276–7283. doi: 10.1158/1078-0432.CCR-03-0692. [DOI] [PubMed] [Google Scholar]
  7. Peters I, Rehmet K, Wilke N, Kuczyk M, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer. 2007;6:49. doi: 10.1186/1476-4598-6-49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497–3508. doi: 10.1158/0008-5472.CAN-04-4088. [DOI] [PubMed] [Google Scholar]
  9. Rabizadeh S, Xavier RJ, Ishiguro K, Bernabeortiz J, Lopez-Ilasaca M, Khokhlatchev A, Mollahan P, Pfeifer GP, Avruch J, Seed B. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem. 2004;279:29247–29254. doi: 10.1074/jbc.M401699200. [DOI] [PubMed] [Google Scholar]
  10. Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res. 2006;66:2785–2793. doi: 10.1158/0008-5472.CAN-05-2303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mathe E. RASSF1A, the new guardian of mitosis. Nat Genet. 2004;36:117–118. doi: 10.1038/ng0204-117. [DOI] [PubMed] [Google Scholar]
  12. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, Lee H, Choi N, Kim J, Kim H, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nature cell biology. 2004;6:129–137. doi: 10.1038/ncb1091. [DOI] [PubMed] [Google Scholar]
  13. Dallol A, Cooper WN, Al-Mulla F, Agathanggelou A, Maher ER, Latif F. Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. Cancer Res. 2007;67:492–500. doi: 10.1158/0008-5472.CAN-06-3604. [DOI] [PubMed] [Google Scholar]
  14. Dallol A, Agathanggelou A, Tommasi S, Pfeifer GP, Maher ER, Latif F. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res. 2005;65:7653–7659. doi: 10.1158/0008-5472.CAN-05-0247. [DOI] [PubMed] [Google Scholar]
  15. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M, Pfeifer GP. Tumor susceptibility of Rassf1a knockout mice. Cancer Res. 2005;65:92–98. [PubMed] [Google Scholar]
  16. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004;10:3972–3979. doi: 10.1158/1078-0432.CCR-04-0175. [DOI] [PubMed] [Google Scholar]
  17. Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma. Oncol Rep. 2004;12:805–810. [PubMed] [Google Scholar]
  18. Waki T, Tamura G, Sato M, Motoyama T. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene. 2003;22:4128–4133. doi: 10.1038/sj.onc.1206651. [DOI] [PubMed] [Google Scholar]
  19. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:2362–2368. [PubMed] [Google Scholar]
  20. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004;10:6119–6125. doi: 10.1158/1078-0432.CCR-04-0652. [DOI] [PubMed] [Google Scholar]
  21. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 2007 doi: 10.1016/j.lungcan.2007.05.011. [DOI] [PubMed] [Google Scholar]
  22. Choi N, Son DS, Song I, Lee HS, Lim YS, Song MS, Lim DS, Lee J, Kim H, Kim J. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int J Cancer. 2005;115:575–581. doi: 10.1002/ijc.20916. [DOI] [PubMed] [Google Scholar]
  23. Mengel M, Kreipe H, von Wasielewski R. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol. 2003;11:261–268. doi: 10.1097/00129039-200309000-00010. [DOI] [PubMed] [Google Scholar]
  24. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) Cancer. 1997;80:992–993. doi: 10.1002/(SICI)1097-0142(19970901)80:5&#x0003c;992::AID-CNCR26&#x0003e;3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  25. Ikuerowo SO, Kuczyk MA, Mengel M, Heyde E van der, Shittu OB, Vaske B, Jonas U, Machtens S, Serth J. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer. 2006;119:867–874. doi: 10.1002/ijc.21869. [DOI] [PubMed] [Google Scholar]
  26. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) 2005;70:576–583. doi: 10.1007/s10541-005-0151-y. [DOI] [PubMed] [Google Scholar]
  27. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691–699. doi: 10.1093/jnci/93.9.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 2007;58:131–138. doi: 10.1016/j.lungcan.2007.05.011. [DOI] [PubMed] [Google Scholar]
  29. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 2004;91:771–774. doi: 10.1038/sj.bjc.6602013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer. 2004;100:1472–1477. doi: 10.1002/cncr.20144. [DOI] [PubMed] [Google Scholar]
  31. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 2006;54:109–116. doi: 10.1016/j.lungcan.2006.06.017. [DOI] [PubMed] [Google Scholar]
  32. Cohen HT, McGovern FJ. Renal-cell carcinoma. The New England journal of medicine. 2005;353:2477–2490. doi: 10.1056/NEJMra043172. [DOI] [PubMed] [Google Scholar]

Articles from BMC Urology are provided here courtesy of BMC

RESOURCES